Premium
Rapid and accurate measurement of anti‐A/B IgG antibody in ABO‐unmatched living donor liver transplantation by surface plasmon resonance
Author(s) -
Yurugi K.,
Kimura S.,
Ashihara E.,
Tsuji H.,
Kawata A.,
Kamitsuji Y.,
Hishida R.,
Takegawa M.,
Egawa H.,
Maekawa T.
Publication year - 2007
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.1365-3148.2007.00737.x
Subject(s) - surface plasmon resonance , abo blood group system , antibody , transplantation , liver transplantation , hemagglutination , immunoglobulin g , chemistry , flow cytometry , medicine , immunology , microbiology and biotechnology , biology , materials science , nanotechnology , nanoparticle
summary High anti‐blood group A or B (anti‐A/B) immunoglobulin G (IgG) haemagglutination titres are associated with poor graft survival in ABO‐unmatched liver transplantation. We have previously reported that the surface plasmon resonance (SPR) method can be used to measure anti‐A/B IgG levels in the plasma very quickly and quantitatively. The aim of this study was to brush up this SPR method. The anti‐A/B IgG antibodies (Abs) were purified from the plasma of healthy volunteers by affinity chromatography and used to establish standard curves for the SPR and flow cytometry (FCM) methods. The haemagglutination test tube (TT), FCM and SPR methods were then used to measure the changes over time in the anti‐A/B IgG titres of 25 ABO‐unmatched living donor liver transplantation (LDLT) recipients. The standard curve permitted the SPR values for the anti‐A/B IgG titres to be expressed in μg mL −1 units. The SPR measurements of the anti‐A/B IgG levels in the LDLT recipients correlated very well with the FCM values, whereas the TT values correlated poorly with either method. Furthermore, the SPR method accurately detected the effects of plasma exchange. In conclusion, the SPR method is an accurate, time‐ and labour‐saving method for measuring anti‐A/B IgG titres that can be easily standardized.